Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropharmacology ; 60(2-3): 223-34, 2011.
Article in English | MEDLINE | ID: mdl-20850464

ABSTRACT

Locus coeruleus degeneration and reduced central noradrenaline content is an early feature of Alzheimer's disease. In transgenic mouse models of Alzheimer's disease-like pathology, lesioning the locus coeruleus exacerbates ß-amyloid (Aß) pathology, neuroinflammation and memory deficits. Here we aimed to determine whether chronic treatment with the α(2)-adrenoceptor antagonist fluparoxan, that enhances noradrenaline release, can prevent the onset of Alzheimer's-like pathology and memory deficits in APP/PS1 transgenic mice (TASTPM). Fluparoxan (1mg/kg/day) was administered to TASTPM and wild type mice from 4 to 8 months of age. Memory was assessed at 4 and 8 months of age using the Morris water maze and contextual fear conditioning and at monthly intervals during the duration of treatment using the object recognition and spontaneous alternation task. Aß plaque load and astrocytosis were measured at 4 and 8 months of age by immunohistochemistry. Fluparoxan treatment prevented age-related spatial working memory deficits in the spontaneous alternation task but not spatial reference memory deficits in the Morris water maze. Aß plaque load and astrocytosis were unaltered by fluparoxan treatment in TASTPM mice. The findings suggest that fluparoxan treatment selectively prevent the decline of forms of memory where noradrenaline plays an integral role and that this beneficial effect is not due to altered Aß plaque pathology or astrocytosis.


Subject(s)
Adrenergic alpha-2 Receptor Antagonists/administration & dosage , Aging , Amyloid beta-Peptides/biosynthesis , Gliosis/drug therapy , Memory Disorders/prevention & control , Piperoxan/analogs & derivatives , Plaque, Amyloid/drug therapy , Pyrroles/administration & dosage , Aging/genetics , Aging/metabolism , Aging/pathology , Amyloid beta-Peptides/genetics , Amyloid beta-Protein Precursor/biosynthesis , Amyloid beta-Protein Precursor/genetics , Animals , Astrocytes/drug effects , Astrocytes/metabolism , Astrocytes/pathology , Gliosis/genetics , Gliosis/metabolism , Humans , Longitudinal Studies , Memory Disorders/genetics , Memory Disorders/metabolism , Mice , Mice, Inbred C57BL , Mice, Transgenic , Piperoxan/administration & dosage , Plaque, Amyloid/genetics , Plaque, Amyloid/metabolism , Presenilin-1/biosynthesis , Presenilin-1/genetics , Receptors, Adrenergic, alpha-2/physiology , Treatment Outcome
2.
Neuroscience ; 164(2): 415-23, 2009 Dec 01.
Article in English | MEDLINE | ID: mdl-19720115

ABSTRACT

Environmental stress produces adverse affects on memory in humans and rodents. Increased noradrenergic neurotransmission is a major component of the response to stress and noradrenaline (NA) plays an important role in modulating processes involved in learning and memory. The present study investigated the effect of NA depletion on stress-induced changes on memory performance in the mouse. Central NA depletion was induced using the selective neurotoxin N-(2-chloroethyl)-N-ethyl-2 bromobenzylamine (DSP-4) and verified by high performance liquid chromatography (HPLC). A novel cage stress procedure involving exposure to a new clean cage for 1 h per day, 4 days per week for 4 weeks, was used to produce stress-induced memory deficits measured using the object recognition task. 50 mg/kg DSP-4 produced large and sustained reductions in NA levels in the frontal cortex and hippocampus measured 24 h, 1 week and 5 weeks after treatment. Four weeks of exposure to novel cage stress induced a memory deficit in the object recognition task which was prevented by DSP-4 pre-treatment (50 mg/kg 1 week before the commencement of stress).These findings indicate that chronic environmental stress adversely affects recognition memory and that this effect is, in part, mediated by the noradrenergic stress response. The implication of these findings is that drugs targeting the noradrenergic system to reduce over-activity may be beneficial in the treatment of stress-related mental disorders such as post-traumatic stress disorder or anxiety in which memory is affected.


Subject(s)
Adrenergic Agents/pharmacology , Benzylamines/pharmacology , Memory Disorders/drug therapy , Memory Disorders/etiology , Norepinephrine/metabolism , Stress, Psychological/complications , Animals , Environment , Frontal Lobe/drug effects , Frontal Lobe/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Hydroxyindoleacetic Acid/metabolism , Male , Memory Disorders/metabolism , Mice , Mice, Inbred C57BL , Neuropsychological Tests , Random Allocation , Recognition, Psychology/drug effects , Recognition, Psychology/physiology , Serotonin/metabolism , Stress, Psychological/metabolism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...